- Title: Biogen resurrects Alzheimer's drug; shares jump 37%
- Date: 22nd October 2019
- Summary: NEW YORK, NEW YORK, UNITED STATES (OCTOBER 22, 2019) (REUTERS) (SOUNDBITE) (English) MIZUHO, HEAD OF BIOTECHNOLOGY RESEARCH, MANAGING DIRECTOR, SENIOR BIOTECHNOLOGY ANALYST, SALIM SYED, SAYING: "So, what's the market's basically implying here is that the company has about, potentially, about a third or maybe even as high as 50 percent odds that the drug will get approved. Obviously, the data set that we got today, whatever was disclosed in the press release, this isn't the cleanest data set that we've seen, but it is better... when a company says that they're going to file, you actually have to move your probability success upwards. And what was in models before today, was virtually zero."
- Embargoed: 5th November 2019 20:22
- Keywords: Biogen Alzheimer's treatment FDA Eisai aducanumab Spinraza Mizuho Salim Syed
- Location: NEW YORK, NEW YORK + CAMBRIDGE, MASSACHUSETTS, UNITED STATES / UNIDENTIFIED LOCATIONS
- City: NEW YORK, NEW YORK + CAMBRIDGE, MASSACHUSETTS, UNITED STATES / UNIDENTIFIED LOCATIONS
- Country: USA
- Topics: Economic Events,Equities Markets
- Reuters ID: LVA002B26KGWD
- Aspect Ratio: 16:9
- Story Text: Biogen on Tuesday (October 22) made a surprising reversal on its Alzheimer's treatment with plans now to seek U.S. regulatory approval, after data from more patients in two discontinued studies showed that the drug improved cognition at high doses.
The drugmaker's shares soared 37% in premarket trade, erasing most of their losses this year that came after it abandoned two studies for the drug.
Biogen and partner Eisai had in March decided to end two late-stage trials of aducanumab based on a so-called "futility analysis" of data, which revealed the trials had little hope of succeeding.
The failure of the treatment, which was widely expected to be Biogen's next blockbuster treatment, spurred demands on Wall Street for it to spend more on product acquisitions at a time when its peers have splurged on billions of dollars in deals.
The company said more data became available after the two studies were discontinued in March, resulting in a larger dataset and a new analysis showed that one of the trials met the main goal, while the other did not.
Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation and language, Biogen said.
Biogen said it plans to submit a marketing application for aducanumab in early 2020 based on discussions with the Food and Drug Administration.
There are no current approved therapies for reversing the decline of Alzheimer's and any successful new treatment is likely to garner billions in sales. Alzheimer's makes up 60-70% of an estimated 50 million cases of dementia globally.
Baird analyst Brian Skorney said an FDA approval for aducanumab is highly unlikely and expects Biogen to have an uphill climb to convince regulators that these results were nothing more than random chance.
Biogen also reported a better-than-expected third-quarter profit. The company's profit beat Wall Street expectations, boosted by higher demand for rare muscle disease drug, Spinraza.
Shares of Biogen, which had lost 25.7% of its value this year as of Monday's (October 21) close, rose to $307 in premarket trade.
(Production: Aleksandra Michalska) - Copyright Holder: REUTERS
- Copyright Notice: (c) Copyright Thomson Reuters 2019. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None